Breo Ellipta 100/25 is a medicine containing the active ingredient(s) fluticasone furoate + vilanterol. On this page you will find out more about Breo Ellipta 100/25, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: fluticasone furoate + vilanterol
Information for medicine and pack size:
Breo Ellipta 100/25 powder for inhalation, 30 actuations
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
COPD,Breo Ellipta is indicated for symptomatic treatment of patients with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.,Breo Ellipta is not indicated for the initiation of bronchodilator therapy in COPD.,Asthma,Breo Ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,Vilanterol, an active ingredient in Breo Ellipta, is a long-acting beta-2-agonist (LABA). A class effect of all LABAs can be an increased risk of asthma death (see Precautions).
Table of characteristics
|Visual appearance||A plastic inhaler with light grey body, pale blue mouthpiece cover and a dose counter, containing two strips of blisters each containing a white powder|
|Dosage Form||Inhalation, powder for|
|Route of administration||Inhalation|
14: Prescription Only Medicine, or Prescription Animal Remedy
30: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Type||Inhaler - dry powder|
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||See Product information for shelf life|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Breo Ellipta 100/25 Powder for inhalation - myDr.com.au
Breo Ellipta 100/25 Powder for inhalation - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Breo Ellipta | myVMC
Fluticasone furoate 100 or 200 micrograms and vilanterol (as trifenatate) 25 micrograms per inhalation
Read more on myVMC – Virtual Medical Centre website
Found 0 results